Modulation of the Astrocyte-Neuron Lactate Shuttle System contributes to Neuroprotective action of Fibroblast Growth Factor 21
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
These results suggest that FGF21 alters metabolic parameters to mediate its neuroprotective functions. Modulation of the astrocyte-neuron lactate shuttle system can be one of the most efficient strategies for FGF21 in Alzheimer-like degeneration and contributes to improvements in brain metabolic defects and amyloid β-induced cytotoxicity. Our findings provide insights into the mechanisms underlying the effects of FGF21 on neurodegeneration and brain energy metabolism and suggest that FGF21 may have therapeutic value in the treatment of AD and other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Pellerin, L., & Magistretti, P. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10625 · Cited by 2,927 · cited 2×
“In particular, there are many studies supporting the astrocyte-neuron lactate shuttle hypothesis [45-48].”
ResultBrain energy metabolism: focus on Astrocyte-neuron metabolic cooperation
Bélanger, M., Allaman, I., & Magistretti, P. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.016 · Cited by 2,313
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 2×
“Tau pathology, oxidative stress and mitochondrial damage are considered the main events along with Aβ insults in the progression and development of AD [3, 4, 54].”
BackgroundAstrocyte-Neuron Lactate Transport Is Required for Long-Term Memory Formation
Suzuki, A., Stern, S. A., Bozdagi, O., Huntley, G. W., Walker, R. H., Magistretti, P. J., & Alberini, C. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.018 · Cited by 1,711
A Cellular Perspective on Brain Energy Metabolism and Functional Imaging
Magistretti, P. J., & Allaman, I. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.035 · Cited by 1,285 · cited 1×
“The brain energy metabolic network is complicated, and while neurons are affected by their own energy metabolic pathways, the energy interaction pathways between astrocytes and neurons are also crucial [36-41].”
BackgroundDifferences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease
West, M. J., Coleman, P. D., Flood, D. G., & Troncoso, J. C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92338-8 · Cited by 1,267 · cited 1×
“The abnormal brain energy metabolism, especially the abnormal energy metabolism of neurons, leads to hippocampal neuron death and eventually AD [35-37].”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 2×
“Among the potential risk factors contributing to AD, diabetes is now receiving increasing attention [9, 10].”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“Unfortunately, in recent years, most mono-target drug candidates designed directly for Aβ or tau have not achieved desirable efficiency in clinical trials [7, 8].”
BackgroundActivity-dependent regulation of energy metabolism by astrocytes: an update
Pellerin, L., Bouzier‐Sore, A., Aubert, A., Serres, S., Merle, M., Costalat, R., & Magistretti, P. J. (2007) · Glia · doi:10.1002/glia.20528 · Cited by 805 · cited 2×
“The evidence from numerous studies supports lactate transfer from astrocytes to neurons and its importance for brain function, and the opposing view suggests that more evidence for the unidirectional flow of lactate from astrocytes to neurons is still needed [46, 47, 49, 50].”
BackgroundResultCerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790 · cited 2×
“According to the viewpoint considering AD as "type 3 diabetes", abnormal brain energy metabolism plays a pivotal role in the occurrence and development of AD [33, 34].”
BackgroundKim, K. H., Jeong, Y. T., Oh, H., Kim, S. H., Cho, J. M., Kim, Y.-N., Kim, S. S., Kim, D. H., Hur, K. Y., Kim, H. K., et al. (2013) · Nature Medicine · doi:10.1038/nm.3014 · Cited by 774 · cited 1×
“Several previous studies have indicated the close ties between autophagy and FGF21 activity [72-75].”
BackgroundZempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686 · cited 1×
“Studies have indicated that Aβ plaques promote tau protein pathology, neuronal damage, and eventually AD [51, 52].”
BackgroundKapogiannis, D., & Mattson, M. P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70277-5 · Cited by 594
Liang, W. S., Reiman, E. M., Valla, J., Dunckley, T., Beach, T. G., Grover, A., Niedzielko, T. L., Schneider, L. E., Mastroeni, D., Caselli, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709259105 · Cited by 585 · cited 3×
“The abnormal brain energy metabolism, especially the abnormal energy metabolism of neurons, leads to hippocampal neuron death and eventually AD [35-37].”
BackgroundIn vivo evidence for a lactate gradient from astrocytes to neurons
Mächler, P., Wyss, M. T., Elsayed, M., Stobart, J., Gutierrez, R., von Faber-Castell, A., Kaelin, V., Zuend, M., San Martín, A., Romero-Gómez, I., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.10.010 · Cited by 571
FGF21 regulates metabolism and circadian behavior by acting on the nervous system
Bookout, A. L., de Groot, M. H. M., Owen, B. M., Lee, S., Gautron, L., Lawrence, H. L., Ding, X., Elmquist, J. K., Takahashi, J. S., Mangelsdorf, D. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3249 · Cited by 545 · cited 1×
“The ability to cross the blood-brain barrier (BBB) and the wide distribution of receptors allow FGF21 to exert direct effects in the central nervous system [28-32].”
BackgroundFGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss
Owen, B. M., Ding, X., Morgan, D. A., Coate, K. C., Bookout, A. L., Rahmouni, K., Kliewer, S. A., & Mangelsdorf, D. J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.012 · Cited by 523 · cited 2×
“FGF21, a hormone that can act on the nervous system through interacting with the receptor, acted centrally to exert its effects on sympathetic nerve activity, energy expenditure and body weight [20].”
BackgroundHow does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492 · cited 2×
“Among the potential risk factors contributing to AD, diabetes is now receiving increasing attention [9, 10].”
BackgroundGauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427 · cited 1×
“Unfortunately, in recent years, most mono-target drug candidates designed directly for Aβ or tau have not achieved desirable efficiency in clinical trials [7, 8].”
BackgroundFGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver
von Holstein-Rathlou, S., BonDurant, L. D., Peltekian, L., Naber, M. C., Yin, T. C., Claflin, K. E., Urizar, A. I., Madsen, A. N., Ratner, C., Holst, B., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.003 · Cited by 347 · cited 1×
“FGF21 is an endocrine hormone that functions as a regulator in energy metabolism, and several target organs and tissues are involved in the diverse activities of FGF21 [20-27].”
BackgroundCraft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335 · cited 1×
“This hypothesis prompted us to search for pharmacotherapy for AD from the pool of endogenous regulators of glucose metabolism, such as insulin, glucagon-like peptide-1, fibroblast growth factor 21 (FGF21), and so on [13-19].”
BackgroundFGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms
BonDurant, L. D., Ameka, M., Naber, M. C., Markan, K. R., Idiga, S. O., Acevedo, M. R., Walsh, S. A., Ornitz, D. M., & Potthoff, M. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.005 · Cited by 330
The fasting polypeptide FGF21 can enter brain from blood
Hsuchou, H., Pan, W., & Kastin, A. J. (2007) · Peptides · doi:10.1016/j.peptides.2007.10.007 · Cited by 280
Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
Staiger, H., Keuper, M., Berti, L., Hrabě de Angelis, M., & Häring, H.-U. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00016 · Cited by 270 · cited 1×
“Overlaps in FGF21 expression and function as well as discrepancies exist between mice and humans; nevertheless, there is a multifunctional liver-brain axis with FGF21 as a pivotal player in mice and humans [58].”
BackgroundLan, T., Morgan, D. A., Rahmouni, K., Sonoda, J., Fu, X., Burgess, S. C., Holland, W. L., Kliewer, S. A., & Mangelsdorf, D. J. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.005 · Cited by 261 · cited 2×
“FGFR1 mainly mediates FGF21 signaling, and the coreceptor KLB is also required for the initiation event [29, 53].”
BackgroundCentral Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice
Douris, N., Stevanovic, D. M., Fisher, F. M., Cisu, T. I., Chee, M. J., Nguyen, N. L., Zarebidaki, E., Adams, A. C., Kharitonenkov, A., Flier, J. S., et al. (2015) · Endocrinology · doi:10.1210/en.2014-2001 · Cited by 215 · cited 1×
“confirmed that FGF21 can act in the brain to activate the sympathetic nervous system and induce adipose tissue thermogenesis [61].”
BackgroundYu, Y., Bai, F., Wang, W., Liu, Y., Yuan, Q., Qu, S., Zhang, T., Tian, G., Li, S., Li, D., et al. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.03.020 · Cited by 119 · cited 2×
“This hypothesis prompted us to search for pharmacotherapy for AD from the pool of endogenous regulators of glucose metabolism, such as insulin, glucagon-like peptide-1, fibroblast growth factor 21 (FGF21), and so on [13-19].”
BackgroundNeuron–astrocyte signaling is preserved in the aging brain
Gómez‐Gonzalo, M., Martin‐Fernandez, M., Martínez‐Murillo, R., Mederos, S., Hernández‐Vivanco, A., Jamison, S., Fernandez, A. P., Serrano, J., Calero, P., Futch, H. S., et al. (2017) · Glia · doi:10.1002/glia.23112 · Cited by 114 · cited 1×
“Physically, the important role of astrocyte-neuron interactions in brain energy metabolism has been summarized and emphasized, and pathologically, extensive evidence indicates that disruption of astrocyte-neuron communications leads to neurodegenerative diseases [38, 42-44].”
Background
Cited by
Lactate metabolism in human health and disease
Li, X., Yang, Y., Zhang, B., Lin, X., Fu, X., An, Y., Zou, Y., Wang, J.-X., Wang, Z., & Yu, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01151-3 · Cited by 1,454
Sun, Y., Zhang, H., Zhang, X., Wang, W., Chen, Y., Cai, Z., Wang, Q., Wang, J., & Shi, Y. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102690 · Cited by 151
Self-citationPhysical Exercise-Induced Myokines in Neurodegenerative Diseases
Lee, B., Shin, M., Park, Y., Won, S.-Y., & Cho, K. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115795 · Cited by 79
“Furthermore, astrocyteneuron lactate shuttle (ANLS) was implicated in decreased tau phosphorylation by FGF21 in a transwell co-culture system with C6 astrocytes and PC12 neurons [208].”
BackgroundTargeting Alzheimer’s Disease: The Critical Crosstalk between the Liver and Brain
Huang, Z., Lin, H. W. (., Zhang, Q., & Zong, X. (2022) · Nutrients · doi:10.3390/nu14204298 · Cited by 50
Metadata
- Authors
- Sun, Y., Wang, Y., Chen, S.-T., Chen, Y.-J., Shen, J., Yao, W.-B., Gao, X.-D., & Chen, S.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2020
- Volume
- 10
- Issue
- 18
- Pages
- 8430-8445
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3043900003
- Cited by
- 93
- References
- 30
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.